Metrika

  • citati u SCIndeksu: [1]
  • citati u CrossRef-u:[3]
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:8
  • preuzimanja u poslednjih 30 dana:4

Sadržaj

članak: 4 od 7  
Back povratak na rezultate
2014, vol. 33, br. 2, str. 169-174
Efekat intervencije folnom kiselinom i vitaminom B12 na vaskularni kognitivni poremećaj komplikovan hiperhomocisteinemijom
The First Hospital Affiliated to the Chinese PLA General Hospital, Department of Neurology, Beijing, China

e-adresabojiangcn@126.com
Ključne reči: kognitivni poremećaj; cerebrovaskularni poremećaj; hiperhomocisteinemija; folna kiselina; vitamin B12
Sažetak
Uvod: Hiperhomocisteinemija (HHcy) nekada koreliše sa kognitivnom funkcijom. Iako se nivo homocisteina (Hcy) snižava posle intervencije folnom kiselinom i vitaminom B12, njihov efekat na kognitivnu funkciju ostaje nejasan. Cilj ove prospektivne studije bio je da se istraži uticaj folne kiseline i vitamina B12 na nivo homocisteina i kognitivnu funkciju kod pacijenata sa vaskularnim kognitivnim poremećajem bez demencije (eng. vascular cognitive impairment - no dementia, VCIND) komplikovanim hiperhomocisteinemijom. Metode: Nasumično je izabrano ukupno 120 pacijenata sa vaskularnim kognitivnim poremećajem bez demencije komplikovanim hiperhomocisteinemijom. Oni su podeljeni u intervencionu i kontrolnu grupu. Intervenciona grupa je primala 5 mg folne kiseline jednom dnevno i 500 μg vitamina B12 tri puta dnevno, uz uobičajenu terapiju. Određeni su nivoi folne kiseline, vitamina B12 i homocisteina a pre i posle tretmana su urađeni kognitivni testovi Montreal Cognitive Assessment (MoCA) i P300 kognitivni potencijal. Rezultati: Pre tretmana, između grupa nisu uočene značajne razlike u nivoima folne kiseline, vitamina B12, homocisteina, niti u parametrima MoCA i P300. Posle tretmana, nivoi folne kiseline i vitamina B12 su porasli, dok se nivo homocisteina u intervencionoj grupi snizio u poređenju sa nivoom pre tretmana i u kontrolnoj grupi. Posle 24 nedelje, u intervencionoj grupi su se popravili rezultati MoCA i P300, u poređenju sa onima pre tretmana i u kontrolnoj grupi. Zakjučak: Folna kiselina i vitamin B12 efikasno snižavaju nivo homocisteina kod pacijenata sa vaskularnim kognitivnim poremećajem bez demencije i poboljšavaju njihove kognitivne funkcije.
Reference
Aisen, P.S., Schneider, L.S., Sano, M., Diaz-Arrastia, R., van Dyck, C.H., Weiner, M.F., et al. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA, 300(15): 1774-1783
Čabarkapa, V., Đerić, M., Stošić, Z., Sakač, V., Davidović, S., Eremić, N. (2013) Determining the relationship between homocysteinemia and biomarkers of inflammation, oxidative stress and functional kidney status in patients with diabetic nephropathy. Journal of Medical Biochemistry, vol. 32, br. 2, str. 131-139
Ebbing, M., Bleie, Ø., Ueland, P.M., Nordrehaug, J.E., Nilsen, D.W., Vollset, S.E., Refsum, H., Ringdal, P.E.K., Nygård, O. (2008) Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA, 300(7): 795-804
Farlow, M.R., He, Y., Tekin, S., Xu, J., Lane, R., Charles, H.C. (2004) Impact of APOE in mild cognitive impairment. Neurology, 63(10): 1898-1901
Folin, M., Baiguera, S., Gallucci, M., Conconi, M.T., di Liddo, R., Zanardo, A., Parnigotto, P.P. (2005) A cross-sectional study of homocysteine-, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology, 6(4): 255-260
Haan, M.N., Miller, J.W., Aiello, A.E., Whitmer, R.A., Jagust, W.J., Mungas, D.M., Allen, L.H., Green, R. (2007) Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. American Journal of Clinical Nutrition, 85(2): 511-517
Herrmann, W., Obeid, R. (2011) Homocysteine: A biomarker in neurodegenerative diseases. Clinical Chemistry and Laboratory Medicine, 49(3): 435-441
Hooshmand, B., Solomon, A., Kåreholt, I., Leiviskä, J., Rusanen, M., Ahtiluoto, S., Winblad, B., Laatikainen, T., Soininen, H., Kivipelto, M. (2010) Homocysteine and holotranscobalamin and the risk of Alzheimer disease: A longitudinal study. Neurology, 75(16): 1408-1414
Karunaratne, S., Hanwella, R., de Silva, V. (2011) Validation of the Sinhala version of the Montreal cognitive assessment in screening for dementia. Ceylon Medical Journal, 56(4): 147-153
Khedr, E.M., Hamed, S.A., El-Shereef, H.K., Shawky, O.A., Mohamed, K.A., Awad, E.M., et al. (2009) Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors. Neuropsychiatr Dis Treat, 5: 103-16
Köseoglu, E., Karaman, Y. (2007) Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clinical Biochemistry, 40(12): 859-863
Loscalzo, J. (2006) Homocysteine trials: Clear outcomes for complex reasons. New England Journal of Medicine, 354(15): 1629-1632
Manolescu, B.N., Oprea, E., Farcasanu, I.C., Berteanu, M., Cercasov, C. (2010) Homocysteine and vitamin therapy in stroke prevention and treatment: A review. Acta biochimica Polonica, 57(4): 467-77
McMahon, J.A., Green, T.J., Skeaff, C. M., Knight, R.G., Mann, J.I., Williams, S.M. (2006) A controlled trial of homocysteine lowering and cognitive performance. New England Journal of Medicine, 354(26): 2764-2772
Moorhouse, P., Rockwood, K. (2008) Vascular cognitive impairment: Current concepts and clinical developments. Lancet Neurol, 7: 246-55
Rockwood, K., Howard, K., Macknight, C., Darvesh, S. (1999) Spectrum of disease in vascular cognitive impairment. Neuroepidemiology, 18(5): 248-254
Sala, I., Belén, S.M., Molina-Porcel, L., Lazaro, E., Gich, I., Clarimon, J., et al. (2008) Homocysteine and cognitive impairment: Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord, 26: 506-12
Saposnik, G., Ray, J.G., Sheridan, P., McQueen, M., Lonn, E. (2009) Homocysteine-lowering therapy and stroke risk, severity, and disability: Additional findings from the HOPE 2 trial. Stroke, 40: 1365-72
Serrano, S., Domingo, J., Rodriguez-Garcia, E., Castro, M.D., Del, S.T. (2007) Frequency of cognitive impairment without dementia in patients with stroke: A two-year follow-up study. Stroke, 38: 105-10
Stephan, B.C.M., Matthews, F.E., Khaw, K., Dufouil, C., Brayne, C. (2009) Beyond mild cognitive impairment: Vascular cognitive impairment, no dementia (VCIND). Alzheimer's Research & Therapy, 1(1): 4-4
Zhang, C., Wei, W., Liu, Y., Peng, J., Tian, Q., Liu, G.H., Zhang, Y.E., Wang, J. (2009) Hyperhomocysteinemia increases β-amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain. American Journal of Pathology, 174(4): 1481-1491
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2478/jomb-2013-0033
objavljen u SCIndeksu: 12.01.2020.